Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: The COBRA study

Arthritis and Rheumatism

Volumn 46, Issue 11, 2002, Pages 2847-2856

  Garnero, Patrick ^a   Landewé, Robert ^b   Boers, Maarten ^c   Verhoeven, Arco ^b   Van Der Linden, Sjef ^b   Christgau, Stephan ^d   Van Der Heijde, Désirée ^b   Boonen, Annelies ^b   Geusens, Piet ^b,e  

^a INSERM   (France)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NORDIC BIOSCIENCE A S   (Denmark)

^e HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; COLLAGEN DERIVATIVE; METHOTREXATE; PREDNISOLONE; PROTEIN CTXI; PROTEIN CTXII; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DEFECT; CARBOXY TERMINAL SEQUENCE; CARTILAGE DEGENERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; JOINT INJURY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SCORING SYSTEM; STATISTICAL MODEL;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; COLLAGEN TYPE I; COLLAGEN TYPE II; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDNISOLONE; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SULFASALAZINE;

EID: 0036846269     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10616     Document Type: Article

References (30)

1. Harris ED. Rheumatoid arthritis: Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
2. Struyk L, Hawes GE, Chatila MK, Breedveld FC, Kurnick JT, van den Elsen PJ. T cell receptors in rheumatoid arthritis. Arthritis Rheum 1995;38:577-89.
3. Klareskog L, Rönnelid J, Holm G. Immunopathogenesis and immunotherapy in rheumatoid arthritis: An area in transition. J Int Med 1995;238:191-206.
4. VanderBorght A, Geusens P, Vandevyver C, Raus J, Stinissen P. Skewed T-cell receptor variable gene usage in the synovium of early and chronic rheumatoid arthritis patients and persistence of clonally expanded T cells in a chronic patient. Rheumatology (Oxford) 2000;39:1189-201.
5. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001;44:1003-12.
6. Möttönen TT. Prediction of erosiveness and rate of development of new erosion in early rheumatoid arthritis. Ann Rheum Dis 1988;47:648-53.
7. Van der Heide A, Remme CA, Hofman DM, Jacobs JWG, Bijlsma JWJ. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995;38:1466-74.
8. Jansen LMA, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BAC. Predictors of radiographic joint damage patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:924-7.
9. Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: A multiparameter prospective study. Arthritis Rheum 2001;44:1736-43.
10. Feigenbaum SL, Masi AT, Kaplan SB. Prognosis in rheumatoid arthritis: A longitudinal study of newly diagnosed younger adult patients. Am J Med 1979;66:377-84.
11. Van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-525.
12. Emery P, Salmon M. Early rheumatoid arthritis: Time to aim for remission? Ann Rheum Dis 1995;54:944-7.
13. Mulherin D, FitzGerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: Evidence that the pathogenesis of synovial inflammation and erosion may differ. Br J Rheumatol 1996;35:1265-8.
14. Kirwan JR. The relationship between synovitis and erosions in rheumatoid arthritis. Br J Rheumatol 1996;35:225-8.
15. Cunnane G, FitzGerald O, Beeton C, Cawston TE, Bresnihan B. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum 2001;44:2263-74.
16. Sharp JT. Radiologic assessment as an outcome measure in rheumatoid arthritis. Arthritis Rheum 1989;32:221-9.
17. Genant HK, Jiang Y, Peterfy C, Lu Y, Rédei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41:1583-90.
18. Garnero P, Rousseau J-C, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 2000;43:953-61.
19. Garnero P, Delmas PD. Biochemical markers of bone turnover in osteoporosis. In: Markus R, Feldman D, Kalsey J, editors. Osteoporosis. San Diego: Academic Press. In press.
20. Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-15.
21. Garnero P, Gineyts E, Christgau S, Fink B, Delmas PD. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:21-30.
22. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:301-9.
23. Landewé RBM, Boers M, Verhoeven AC, Westhovens R, van de Laar MAFJ, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
25. Prevoo MLL, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
26. Sharp JT, Lidsky MD, Collins LS, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-20.
27. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-5.
28. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:307-10.
29. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337-49.
30. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1473-7.